Piper Jaffray Companies Reaffirms “Hold” Rating for Fluidigm (FLDM)

Fluidigm (NASDAQ:FLDM)‘s stock had its “hold” rating reiterated by investment analysts at Piper Jaffray Companies in a report issued on Thursday. They presently have a $6.10 target price on the medical research company’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 5.54% from the company’s previous close.

Separately, ValuEngine downgraded Fluidigm from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.

Fluidigm (NASDAQ FLDM) traded down $0.02 during trading on Thursday, reaching $5.78. The company had a trading volume of 163,263 shares, compared to its average volume of 175,502. Fluidigm has a fifty-two week low of $2.52 and a fifty-two week high of $7.05. The company has a current ratio of 3.02, a quick ratio of 2.46 and a debt-to-equity ratio of 5.00. The stock has a market capitalization of $222.22, a P/E ratio of -2.58 and a beta of 3.24.

Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.17. Fluidigm had a negative return on equity of 134.35% and a negative net margin of 68.27%. The business had revenue of $27.75 million for the quarter, compared to the consensus estimate of $27.14 million. During the same quarter in the prior year, the business earned ($0.32) earnings per share. Fluidigm’s revenue for the quarter was up 10.6% on a year-over-year basis. equities analysts anticipate that Fluidigm will post -1.4 earnings per share for the current year.

In other news, insider Levin Capital Strategies, L.P. acquired 20,380 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average price of $5.71 per share, for a total transaction of $116,369.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders purchased 482,624 shares of company stock worth $2,917,895. 4.70% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the business. Virtu KCG Holdings LLC purchased a new stake in shares of Fluidigm during the second quarter worth $105,000. Sei Investments Co. lifted its position in shares of Fluidigm by 221.7% during the third quarter. Sei Investments Co. now owns 21,668 shares of the medical research company’s stock worth $109,000 after acquiring an additional 14,932 shares in the last quarter. Group One Trading L.P. lifted its position in shares of Fluidigm by 336.9% during the third quarter. Group One Trading L.P. now owns 23,155 shares of the medical research company’s stock worth $117,000 after acquiring an additional 17,855 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Fluidigm during the third quarter worth $123,000. Finally, Alliancebernstein L.P. lifted its position in shares of Fluidigm by 18.4% during the second quarter. Alliancebernstein L.P. now owns 45,700 shares of the medical research company’s stock worth $185,000 after acquiring an additional 7,100 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Piper Jaffray Companies Reaffirms “Hold” Rating for Fluidigm (FLDM)” was published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/08/piper-jaffray-companies-reaffirms-hold-rating-for-fluidigm-fldm.html.

About Fluidigm

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply